ReviewNanomedicine (London, England)2018
Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells.
Review in Nanomedicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Synthetic Strategy for mRNA Encapsulation and Gene Delivery with Nanoscale Metal-Organic Frameworks.Advanced functional materials · 2025Article
- An overview of randomized phase III clinical trials of cancer nanomedicines.Cancer pathogenesis and therapy · 2025Review
- Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025Review
- Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection.Biomaterials · 2024Article
- In Silico Screening Accelerates Nanocarrier Design for Efficient mRNA Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics.Advanced drug delivery reviews · 2023Review
- Landscape of NcRNAs involved in drug resistance of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Aptamer-engineered (nano)materials for theranostic applications.Theranostics · 2023Review
- Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection.Pharmaceutics · 2022Review
- Non-invasive gene delivery across the blood-brain barrier: present and future perspectives.Neural regeneration research · 2022Article
- Strategies to deliver RNA by nanoparticles for therapeutic potential.Molecular aspects of medicine · 2022Review
- Non-viral vectors for RNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Trends and Hotspots in Nanoparticles for the Targeted Delivery of Nucleic Acids: A Ten-Year Bibliometric Study.Frontiers in pharmacology · 2022Article
- Animal models used in the research of nanoparticles for cardiovascular diseases.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2021Review
- Opportunities, Barriers, and a Strategy for Overcoming Translational Challenges to Therapeutic Nucleic Acid Nanotechnology.ACS nano · 2020Article
- Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?Non-coding RNA research · 2020Review
- Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Counterion of Chitosan Influences Thermodynamics of Association of siRNA with a Chitosan-Based siRNA Carrier.Pharmaceutical research · 2020Article
- Noncoding RNAs in cancer therapy resistance and targeted drug development.Journal of hematology & oncology · 2019Review
- Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.Bioconjugate chemistry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This review presents an integrated analysis of the current-state-of-the-art in nucleic acid nanotherapies and highlights the importance of nanotechnology in the delivery of nucleic acid therapies. While there is no one dominant nanodesign, the diversity of nanodesigns and delivery of different siRNAs, miRNA and DNA to inhibit more than 20 targets in seven disease states in Phase II/III clinical trials reflects the potential of nucleic acid therapies to treat intractable diseases and non-druggable targets. We provide benchmarks to aid in comparing the design, proof-of-concept studies and clinical trials. From this, we demonstrate the importance of generating a strategic framework for integrating clinical 'wish lists' for a means to treat intractable diseases with engineering 'design checklists' for nucleic acid nanotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.